keyword
https://read.qxmd.com/read/37711900/the-clinical-and-therapeutic-profiles-of-prolactinomas-associated-with-germline-pathogenic-variants-in-the-aryl-hydrocarbon-receptor-interacting-protein-aip-gene
#41
JOURNAL ARTICLE
Laurent Vroonen, Albert Beckers, Severine Camby, Thomas Cuny, Pablo Beckers, Marie-Lise Jaffrain-Rea, Muriel Cogne, Luciana Naves, Amandine Ferriere, Pauline Romanet, Atanaska Elenkova, Auli Karhu, Thierry Brue, Anne Barlier, Patrick Pétrossians, Adrian F Daly
INTRODUCTION: Prolactinomas are the most frequent type of pituitary adenoma encountered in clinical practice. Dopamine agonists (DA) like cabergoline typically provide sign/ symptom control, normalize prolactin levels and decrease tumor size in most patients. DA-resistant prolactinomas are infrequent and can occur in association with some genetic causes like MEN1 and pathogenic germline variants in the AIP gene (AIPvar). METHODS: We compared the clinical, radiological, and therapeutic characteristics of AIPvar-related prolactinomas (n=13) with unselected hospital-treated prolactinomas ("unselected", n=41) and genetically-negative, DA-resistant prolactinomas (DA-resistant, n=39)...
2023: Frontiers in Endocrinology
https://read.qxmd.com/read/37625240/efficacy-of-pd-1-inhibitors-for-colorectal-cancer-and-polyps-in-lynch-syndrome-patients
#42
JOURNAL ARTICLE
Jie-Hai Yu, Bin-Yi Xiao, Jing-Hua Tang, Dan-Dan Li, Fang Wang, Ya Ding, Kai Han, Ling-Heng Kong, Yi-Hong Ling, Wei-Jian Mei, Zhi-Gang Hong, Le-En Liao, Wan-Jun Yang, Zhi-Zhong Pan, Xiao-Shi Zhang, Wu Jiang, Pei-Rong Ding
BACKGROUND: Programmed death-1 (PD-1) inhibitor is effective for colorectal cancer (CRC) with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). We aimed to explore its effects on CRCs and colonic polyps in Lynch syndrome (LS) patients. METHODS: LS patients with CRC who had evaluable tumours and received at least 2 cycles of PD-1 inhibitors were retrospectively included. PD-1 inhibitors were given as a monotherapy or in combination with other therapies, including anticytotoxic T-lymphocyte-associated antigen-4 treatment, radiotherapy, chemotherapy, and targeted therapy...
October 2023: European Journal of Cancer
https://read.qxmd.com/read/37584889/the-potential-link-between-acromegaly-and-risk-of-acute-ischemic-stroke-in-patients-with-pituitary-adenoma-a-new-perspective
#43
REVIEW
Saud A Alnaaim, Hayder M Al-Kuraishy, Mohammad Mitran Zailaie, Athanasios Alexiou, Marios Papadakis, Hebatallah M Saad, Gaber El-Saber Batiha
Acromegaly is an endocrine disorder due to the excess production of growth hormone (GH) from the anterior pituitary gland after closed epiphyseal growth plates. Acromegaly is mainly caused by benign GH-secreting pituitary adenoma. Acute ischemic stroke (AIS) is one of the most common cardiovascular complications. It ranks second after ischemic heart disease (IHD) as a cause of disability and death in high-income countries globally. Thus, this review aimed to elucidate the possible link between acromegaly and the development of AIS...
August 16, 2023: Acta Neurologica Belgica
https://read.qxmd.com/read/37579837/position-statement-on-the-diagnosis-and-management-of-acromegaly-the-french-national-diagnosis-and-treatment-protocol-ndtp
#44
Thierry Brue, Haïfa Rahabi, Abdoulaye Barry, Anne Barlier, Jérôme Bertherat, Françoise Borson-Chazot, Frédéric Castinetti, Laure Cazabat, Olivier Chabre, Nicolas Chevalier, Sophie Christin-Maitre, Christine Cortet, Delphine Drui, Peter Kamenicky, Catherine Lançon, Frédéric Lioté, Isabelle Pellegrini, Rachel Reynaud, Sylvie Salenave, Igor Tauveron, Philippe Touraine, Marie-Christine Vantyghem, Bruno Vergès, Delphine Vezzosi, Chiara Villa, Gérald Raverot, Régis Coutant, Philippe Chanson, Frederique Albarel
Acromegaly is a rare disease with prevalence of approximately 60 cases per million, slight female predominance and peak onset in adults in the fourth decade. Clinical diagnosis is often delayed by several years due to the slowly progressive onset of symptoms. There are multiple clinical criteria that define acromegaly: dysmorphic syndrome of insidious onset, symptoms related to the pituitary tumor (headaches, visual disorders), general signs (sweating, carpal tunnel syndrome, joint pain, etc.), complications of the disease (musculoskeletal, cardiovascular, pneumological, dental, metabolic comorbidities, thyroid nodules, colonic polyps, etc...
August 12, 2023: Annales D'endocrinologie
https://read.qxmd.com/read/37551511/pituitary-function-before-and-after-surgery-for-nonfunctioning-pituitary-adenomas-data-from-the-swedish-pituitary-register
#45
JOURNAL ARTICLE
Nasrin Al-Shamkhi, Katarina Berinder, Henrik Borg, Pia Burman, Per Dahlqvist, Charlotte Höybye, Daniel S Olsson, Oskar Ragnarsson, Bertil Ekman, Britt Edén Engström
OBJECTIVE: Data on pre- and postoperative pituitary function in nonfunctioning pituitary adenomas (NFPA) are not consistent. We aimed to investigate pituitary function before and up to five years after transsphenoidal surgery with emphasis on the hypothalamic-pituitary-adrenal axis (HPA). DESIGN AND METHODS: Data from the Swedish Pituitary Register was used to analyze anterior pituitary function in 838 patients with NFPA diagnosed between 1991 and 2014. Patients who were reoperated or had received radiotherapy were excluded...
August 8, 2023: European Journal of Endocrinology
https://read.qxmd.com/read/37529607/therapeutic-response-to-pazopanib-case-report-and-literature-review-on-molecular-abnormalities-of-aggressive-prolactinomas
#46
REVIEW
Eduardo J Medina, Youssef M Zohdy, Edoardo Porto, Juan M Revuelta Barbero, David Bray, Justin Maldonado, Alejandra Rodas, Miguel Mayol, Bryan Morales, Stewart Neill, William Read, Gustavo Pradilla, Adriana Ioachimescu, Tomas Garzon-Muvdi
INTRODUCTION: Aggressive prolactinomas (APRLs) pose a significant clinical challenge due to their high rate of regrowth and potentially life-threatening complications. In this study, we present a case of a patient with an APRL who had a trial of multiple therapeutic modalities with the aim to provide a review of molecular abnormalities and management of APRLs by corroborating our experience with previous literature. METHODS: A total of 268 articles were reviewed and 46 were included...
2023: Frontiers in Endocrinology
https://read.qxmd.com/read/37516994/-aggressive-pituitary-adenoma-and-pituitary-carcinoma
#47
JOURNAL ARTICLE
Miklós Tóth
Anterior pituitary tumours, once considered benign neoplasms, may rarely have aggressive behaviour and can even metastasize. The current guideline of the European Society of Endocrinology defines aggressive pituitary adenomas as radiologically invasive tumours with an unusually rapid growth rate and frequent relapses despite the optimal use of standard therapies. Currently, there is not any single, well-defined pathological marker of malignancy. Pituitary carcinomas are thus clinically defined by the presence of craniospinal or distant metastases, typically developing several years after the first presentation...
July 30, 2023: Orvosi Hetilap
https://read.qxmd.com/read/37501881/non-functioning-pituitary-macroadenoma-following-surgery-long-term-outcomes-and-development-of-an-optimal-follow-up-strategy
#48
JOURNAL ARTICLE
Ziad Hussein, Joan Grieve, Neil Dorward, Katherine Miszkiel, Michael Kosmin, Naomi Fersht, Pierre Marc Bouloux, Zane Jaunmuktane, Stephanie E Baldeweg, Hani J Marcus
OBJECTIVES: Recurrence and regrowth of non-functioning pituitary macroadenomas (NFPMs) after surgery are common but remain unpredictable. Therefore, the optimal timing and frequency of follow-up imaging remain to be determined. We sought to determine the long-term surgical outcomes of NFPMs following surgery and develop an optimal follow-up strategy. METHODS: Patients underwent surgery for NFPMs between 1987 and 2018, with a follow-up of 6 months or more, were identified...
2023: Frontiers in Surgery
https://read.qxmd.com/read/37462809/the-clinicopathological-features-and-prognosis-of-silent-corticotroph-tumors-an-updated-systematic-review-and-meta-analysis
#49
JOURNAL ARTICLE
Huy Gia Vuong, Ian F Dunn
INTRODUCTION: Data on silent corticotroph tumor (SCT) are still heterogeneous and controversial. In this study, we aimed to compare the demographic, clinicopathological manifestations, postoperative complications, and patient outcomes of SCTs with other non-functioning pituitary neuroendocrine tumor (NFT) and functioning corticotroph tumor (FCT) or so-called Cushing disease adenoma. METHODS: We searched PubMed and Web of Science for data of interest. Odds ratio (OR), mean difference (MD), hazard ratio (HR), and their 95% confidence intervals (CI) were pooled using the random-effect model...
July 18, 2023: Endocrine
https://read.qxmd.com/read/37428396/the-treatment-of-aggressive-prolactinomas-with-everolimus
#50
REVIEW
Andrew L Lin, Eliza B Geer, Nupur Lala, Gabrielle Page-Wilson, Rajiv Magge, Robert J Young, Viviane Tabar
INTRODUCTION: Aggressive prolactinomas are life-limiting tumors without a standard of care treatment option after the oral alkylator, temozolomide, fails to provide tumor control. METHODS: We reviewed an institutional database of pituitary tumors for patients with aggressive prolactinomas who progressed following treatment with a dopamine receptor agonist, radiotherapy and temozolomide. Within this cohort, we identified four patients who were treated with everolimus and we report their response to this therapy...
August 2023: Pituitary
https://read.qxmd.com/read/37404513/pituicytoma-a-rare-tumor-of-the-sella-a-case-report-and-review-of-literature-for-diagnosis-and-management
#51
Umaima Zaki, Areesha Syeda Shakeel, Yaseen Rauf, Muhammad Raza
BACKGROUND: Pituicytomas are rare tumors of the pituitary gland derived from the ependymal cells and line the pituitary stalk and posterior lobe. These tumors are located in the vulnerable regions of the brain: Either in the sellar or suprasellar area. The location marks the difference in the clinical features of the tumor. Here, we report a case of histopathologically diagnosed pituicytoma of the sellar region. Literature is also reviewed and discussed to gain a better understanding of this rare disease...
2023: Surgical Neurology International
https://read.qxmd.com/read/37401289/a-pharmacophore-screening-approach-of-homeopathic-phenols-for-a-renovated-design-of-fragment-optimized-bauhiniastatin-1-as-a-drug-against-acromegaly
#52
JOURNAL ARTICLE
M Naveed, N Ain, T Aziz, K Javed, H Ishfaq, S Khalil, M Alharbi, A Alshammari, A F Alasmari
OBJECTIVE: Acromegaly is a fatal and chronic disease that is caused by the abnormal secretion of growth hormone (GH) by the pituitary adenoma or pituitary tumor, resulting in an increased circulated concentration of insulin-like growth factors 1 (IGF-1), where in most of the cases it is secreted by a pituitary tumor. Higher levels of GH cause an increase in IGF-1 in the liver leading to multiple conditions such as cardiovascular diseases, glucose imbalance, cancer, and sleep apnea. Medical treatments such as surgery and radiotherapy can be used as the first choice of patients; however, specified human growth hormone control should be an essential treatment strategy due to an incidence rate of 0...
June 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/37401055/cushing-disease-in-pediatrics-an-update
#53
JOURNAL ARTICLE
Marcio José Concepción-Zavaleta, Cristian David Armas, Juan Eduardo Quiroz-Aldave, Eilhart Jorge García-Villasante, Ana Cecilia Gariza-Solano, María Del Carmen Durand-Vásquez, Luis Alberto Concepción-Urteaga, Francisca Elena Zavaleta-Gutiérrez
Cushing disease (CD) is the main cause of endogenous Cushing syndrome (CS) and is produced by an adrenocorticotropic hormone (ACTH)-producing pituitary adenoma. Its relevance in pediatrics is due to the retardation of both growth and developmental processes because of hypercortisolism. In childhood, the main features of CS are facial changes, rapid or exaggerated weight gain, hirsutism, virilization, and acne. Endogenous hypercortisolism should be established after exogenous CS has been ruled out based on 24-hour urinary free cortisol, midnight serum or salivary cortisol, and dexamethasone suppression test; after that, ACTH dependence should be established...
June 2023: Annals of Pediatric Endocrinology & Metabolism
https://read.qxmd.com/read/37389776/postsurgical-outcomes-of-nonfunctioning-pituitary-adenomas-a-patient-level-meta-analysis
#54
JOURNAL ARTICLE
Khi Yung Fong, Mervyn Jun Rui Lim, Shuning Fu, Chen Ee Low, Yiong Huak Chan, Doddabele Srinivasa Deepak, Xinni Xu, Mark Thong, Swati Jain, Kejia Teo, Paul A Gardner, Carl H Snyderman, Vincent Diong Weng Nga, Tseng Tsai Yeo
BACKGROUND: Surgical resection is the main treatment for symptomatic nonfunctioning pituitary adenomas (NFPA). We aimed to analyze the impact of surgical approach, completeness of resection, and postoperative radiotherapy on long-term progression-free survival (PFS) of NFPA, using individual patient data (IPD) meta-analysis. METHODS: An electronic literature searched was conducted on PubMed, EMBASE, and Web of Science from database inception to 6 November 2022. Studies describing the natural history of surgically resected NFPA, with provision of Kaplan-Meier curves, were included...
August 2023: Pituitary
https://read.qxmd.com/read/37389717/pituitary-function-at-presentation-and-following-therapy-in-patients-with-non-functional-pituitary-macroadenomas-a-single-centre-retrospective-cohort-study
#55
JOURNAL ARTICLE
Ziad Hussein, Hani J Marcus, Joan Grieve, Neil Dorward, Michael Kosmin, Naomi Fersht, Pierre Marc Bouloux, Zane Jaunmuktane, Stephanie E Baldeweg
BACKGROUND: Non-functioning pituitary macroadenomas (NFPMs) may present with hypopituitarism. Pituitary surgery and radiotherapy pose an additional risk to pituitary function. OBJECTIVES: To assess the incidence of hypopituitarism at presentation, the impact of treatment, and the likelihood of endocrine recovery during follow-up. METHODS: All patients treated surgically with and without radiotherapy for NFPMs between 1987 and 2018 who had longer than six months follow-up were identified...
October 2023: Endocrine
https://read.qxmd.com/read/37345108/post-operative-medium-and-long-term-endocrine-outcomes-in-patients-with-non-functioning-pituitary-adenomas-machine-learning-analysis
#56
JOURNAL ARTICLE
Ziad Hussein, Robert W Slack, Hani J Marcus, Evangelos B Mazomenos, Stephanie E Baldeweg
Post-operative endocrine outcomes in patients with non-functioning pituitary adenoma (NFPA) are variable. The aim of this study was to use machine learning (ML) models to better predict medium- and long-term post-operative hypopituitarism in patients with NFPAs. We included data from 383 patients who underwent surgery with or without radiotherapy for NFPAs, with a follow-up period between 6 months and 15 years. ML models, including k-nearest neighbour (KNN), support vector machine (SVM), and decision tree models, showed a superior ability to predict panhypopituitarism compared with non-parametric statistical modelling (mean accuracy: 0...
May 16, 2023: Cancers
https://read.qxmd.com/read/37319160/natural-history-of-pituitary-apoplexy-a-long-term-follow-up-study
#57
JOURNAL ARTICLE
Ayesha A Shaikh, David Michael Williams, Jeffrey Wayne Stephens, Kusuma Boregowda, Maneesh Vasanth Udiawar, David E Price
BACKGROUND AND AIMS: Pituitary apoplexy (PA) is a rare neurosurgical emergency, associated with deficiency of one or more pituitary hormones. Few studies have explored the relative outcomes associated with conservative and neurosurgical intervention. METHODS: A retrospective evaluation of all patients with PA reviewed at Morriston Hospital was undertaken and diagnosis was obtained from Morriston database (Leicester Clinical Workstation database) between 1998 and 2019 from clinic letters and discharge summaries...
June 15, 2023: Postgraduate Medical Journal
https://read.qxmd.com/read/37316636/refractory-somatotroph-adenomas
#58
REVIEW
Monica R Gadelha, Leandro Kasuki
Somatotroph adenomas are usually controlled with standard therapy, which can include surgery, medical treatment and radiotherapy. Some tumors have a more aggressive behavior and are refractory to standard therapy. In this review, we summarize the phenotype of these tumors and the current options for their management.
June 2023: Pituitary
https://read.qxmd.com/read/37275042/a-rare-case-of-extraosseous-osteosarcoma-eos-of-parotid-gland
#59
JOURNAL ARTICLE
Surendra K Dabas, Nandini N Menon, Reetesh Ranjan, Ashwani Sharma, Bikas Gurung, Himanshu Shukla, Hitesh Dawar, Sukirti Tiwari, Ajit Sinha, Rishu Singal, Sahibinder Singh Bhatti, Aditi Dua
Extraosseous osteosarcoma is a rare malignant soft tissue neoplasm, and extraosseous osteosarcoma of the parotid gland is very rare. It has a very aggressive course, and there are no standardized treatment guidelines. We report the case of a 20 year old male patient who presented with history of right neck swelling since 6 years for which he had undergone right parotid surgery 5 years ago. The final histopathological report indicated that the mass was a pleomorphic adenoma. One year after the first surgery, the patient experienced recurrence of swelling over the operated site, and the size of the swelling has been increasing gradually since then...
June 2023: Indian Journal of Otolaryngology and Head and Neck Surgery
https://read.qxmd.com/read/37269766/non-functioning-pituitary-carcinoma-case-report-and-literature-review
#60
Najoua Messaoudi, Imane Assarrar, Siham Rouf, Sanae Sefiani, Hanane Latrech
INTRODUCTION AND IMPORTANCE: Non-functional pituitary carcinoma is a rare neuroendocrine tumor. It is characterized by the presence of cerebrospinal or distant metastasis of an adenohypophysis tumor without any hypersecretion. Only a few cases of non-functional pituitary carcinomas have been reported in the literature. CASE PRESENTATION: In this paper, we report the case of a 48-year-old female patient who presented with spinal pain and a mass facing the second thoracic vertebrae...
June 1, 2023: International Journal of Surgery Case Reports
keyword
keyword
74547
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.